The risk and nature of flares in juvenile idiopathic arthritis: Results from the ReACCh-Out cohort

Annals of the Rheumatic Diseases

Volumn 75, Issue 6, 2016, Pages 1092-1098

  Guzman, Jaime ^a   Oen, Kiem ^b   Huber, Adam M ^c   Duffy, Karen Watanabe ^d   Boire, Gilles ^e   Shiff, Natalie ^f   Berard, Roberta A ^g   Levy, Deborah M ^h   Stringer, Elizabeth ^c   Scuccimarri, Rosie ⁱ   Morishita, Kimberly ^a   Johnson, Nicole ^j   Cabral, David A ^a   Rosenberg, Alan M ^f   Larché, Maggie ^k   Dancey, Paul ^l   Petty, Ross E ^a   Laxer, Ronald M ^h   Silverman, Earl ^h   Miettunen, Paivi ^j   Chetaille, Anne Laure ^m   Haddad, Elie ⁿ   Houghton, Kristin ^a   Spiegel, Lynn ^h   Turvey, Stuart E ^a   Schmeling, Heinrike ^j   Lang, Bianca ^c   Ellsworth, Janet ^o   Ramsey, Suzanne E ^c   Bruns, Alessandra ^e   Roth, Johannes ^d   Campillo, Sarah ⁱ   Benseler, Susanne ^j   Chédeville, Gaëlle ⁱ   Schneider, Rayfel ^h   Tse, Shirley M L ^h   Bolaria, Roxana ^a   Gross, Katherine ^a   Feldman, Brian ^h   Feldman, Debbie ^p   Cameron, Bonnie ^h   Jurencak, Roman ^d   Dorval, Jean ^m   LeBlanc, Claire ⁱ   St Cyr, Claire ⁿ   Gibbon, Michele ^d   Yeung, Rae S M ^h   Duffy, Ciarán M ^d   Tucker, Lori B ^a   more..

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^f ROYAL UNIVERSITY HOSPITAL   (Canada)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

^h HOSPITAL FOR SICK CHILDREN   (Canada)

ⁱ MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^j UNIVERSITY OF CALGARY   (Canada)

^k MCMASTER UNIVERSITY   (Canada)

^l MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^m LAVAL UNIVERSITY   (Canada)

ⁿ UNIVERSITY OF MONTREAL   (Canada)

^o UNIVERSITY OF ALBERTA   (Canada)

^p UNIVERSITÉ DE MONTRÉAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; RHEUMATOID FACTOR; ANTIRHEUMATIC AGENT; BIOLOGICAL FACTOR;

ANTIBODY DETECTION; ARTICLE; CHILD; CLINICAL ASSESSMENT; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; ARTHRITIS, JUVENILE; BLOOD; CANADA; DISEASE COURSE; FEMALE; KAPLAN MEIER METHOD; MALE; OUTCOME ASSESSMENT; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX; TIME FACTOR;

ANTIBODIES, ANTINUCLEAR; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; BIOLOGICAL FACTORS; CANADA; CHILD; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECURRENCE; RHEUMATOID FACTOR; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84969969934     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-207164     Document Type: Article

References (27)

1. Guzman J, Oen K, Tucker LB, et al, for the ReACCh-Out investigators. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis 2015;74: 1854-60.
2. Guzman J, Gómez-Ramírez O, Jurencak R, et al. What matters most for patients, parents, and clinicians in the course of juvenile idiopathic arthritis? A qualitative study. J Rheumatol 2014;41:2260-9.
3. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
4. Lanni S, Bertamino M, Consolaro A, et al. Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis. Rheumatology (Oxford) 2011;50:1627-34.
5. Papadopoulou C, Kostik M, Gonzalez-Fernandez MI, et al. Delineating the role of multiple intraarticular corticosteroid injections in the management of juvenile idiopathic arthritis in the biologic era. Arthritis Care Res (Hoboken) 2013;65:1112-20.
6. Foell D, Wulffraat N, Wedderburn LR, et al, Paediatric Rheumatology International Trials Organization (PRINTO). Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 2010;303:1266-73.
7. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9.
8. Brunner HI, Lovell DJ, Finck BK, et al. Preliminary definition of disease flare in juvenile rheumatoid arthritis. J Rheumatol 2002;29:1058-64.
9. Oen K, Tucker L, Huber AM, et al. Predictors of early inactive disease in a juvenile idiopathic arthritis cohort: results of a Canadian multicenter, prospective inception cohort study. Arthritis Rheum 2009;61:1077-86.
10. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
11. Wallace CA, Ruperto N, Giannini EH, for the CARRA, PRINTO and PRCSG. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290-4.
12. Bingham CO 3rd, Pohl C, Woodworth TG, et al. Developing a standardized definition for disease "flare" in rheumatoid arthritis (OMERACT 9 Special Interest Group). J Rheumatol 2009;36:2335-41.
13. Oen K. Long-term outcomes and predictors of outcomes for patients with juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol 2002;16:347-60.
14. Ravelli A, Martini A. Early predictors of outcome in juvenile idiopathic arthritis. Clin Exp Rheumatol 2003;21(5 Suppl 31):S89-93.
15. Adib N, Silman A, Thomson W. Outcome following onset of juvenile idiopathic inflammatory arthritis: II. Predictors of outcome in juvenile arthritis. Rheumatology (Oxford) 2005;44:1002-7.
16. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 2011;63:465-82.
17. Singh-Grewal D, Schneider R, Bayer N, et al. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum 2006;54:1595-601.
18. Lovell DJ, Ruperto N, Goodman S, et al, Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810-20.
19. Ruperto N, Lovell DJ, Quartier P, et al, Paediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008;372:383-91.
20. Ravelli A, Varnier GC, Oliveira S, et al. Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. Arthritis Rheum 2011;63:267-75.
21. Wallace CA, Giannini EH, Huang B, et al. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2011;63:929-36.
22. Ruperto N, Lovell DJ, Quartier P, et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 2010;62:1792-802.
23. Ringold S, Seidel KD, Koepsell TD, et al. Inactive disease in polyarticular juvenile idiopathic arthritis: current patterns and associations. Rheumatology (Oxford) 2009;48:972-7.
24. Wallace CA, Huang B, Bandeira M, et al. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum 2005;52:3554-62.
25. Berard RA, Tomlinson G, Li X, et al. Description of active joint count trajectories in juvenile idiopathic arthritis. J Rheumatol 2014;41:2466-73.
26. Consolaro A, Negro G, Chiara Gallo M, et al. Defining criteria for disease activity states in nonsystemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity score. Arthritis Care Res (Hoboken) 2014;66:1703-9.
27. Eng SW, Duong TT, Rosenberg AM, et al, on behalf of the REACCH OUT and BBOP Research Consortia. The biological basis for clinical heterogeneity in childhood arthritis. Arthritis Rheumatol 2014;66:3463-75.